ClinicalTrials.gg
RecruitingNCT04930029OMEGA10Updated Dec 26, 2025

Evaluation of Long-term Adverse Effects of Gastric Bypass in Omega

An observational study in Bypass Complication and Obesity, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by University Hospital, Lille · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
320
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Obesity by University Hospital, Lille — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University Hospital, Lille.

Planned enrollment
4th of 15
320 · median 134
Started
2021
with 2 others
Observational
15 of 23
3 open now
Registered
22nd of 23
by date

Among the 23 studies in Obesity by University Hospital, Lille, this one is the 4th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2021, is one of 15 observational ones, and was the 22nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 23 studies in Obesity by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Obesity by University Hospital, Lille, or all of them as a file.
02

Study summary

The omega gastric bypass (OAGB) is developing worldwide as an alternative to the Y gastric bypass (RYGB). Cases of nutrition deficiency after OAGB, in particular protein deficency, are regularly reported in the literature, raising the question of the medium/long-term safety of this procedure. In its technology assessment report issued in September 2019 (HAS, 2019), the Haute Autorité de Santé rules on the invalidity of OAGB with a 200 cm biliary limb and the lack of sufficient data on the safety of OAGB with a 150 cm biliary limb compared to RYGB. The lack of long-term data on weight, resolution of comorbidities, quality of life, and endoscopic evaluation given the risk of lower esophageal cancer is also noted.

The main objective of the study is to compare the incidence of serious adverse events related to surgery after OAGB at 10 years, according to 2 types of loop: a realization with a 150-cm biliary loop (OAGB AB150) versus a realization with a 200-cm biliary loop (OAGB AB200).

03

Conditions studied

  • Bypass Complication
  • Obesity

Keywords

  • One anastomosis gastric bypass
  • obesity
  • bariatric surgery
  • GERD
  • long term
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study involves patients:

  • operated between 2008 and 2013 for an OAGB with a 150 or 200cm biliary limb
  • fulfilling the HAS criteria(HAS, 2009) at the time of their surgery: BMI ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 associated with a comorbidity likely to be improved by weight loss
  • benefiting from a follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who received 10 ± 2 years ago (between 2009 and 2013) an OAGB with a 150 or 200cm biliary limb. Patients should be consecutive at each center.
  • Patients fulfilling the criteria of indication for bariatric surgery at the time of their intervention according to the recommendations of the HAS (HAS, 2009) in an expert center.
  • Patients agreeing to perform an endoscopic evaluation with at 10 years
  • Patients who gave their consent
  • Patients with health insurance coverage

Exclusion criteria

Exclusion Criteria:

  • to bariatric surgery defined according to HAS recommendations (HAS, 2009)
  • Persons deprived of liberty, under guardianship, or under curatorship
  • Patients included in a protocol with a conflict of interest with OMEGA10.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
320 participants (estimated)
Patient registry
No

Groups and cohorts

  • OAGB150

    One anastomosis gastric bypass with 150cm biliary limb

    Other: Ten year evaluation

  • OAGB200

    One anastomosis gastric bypass with 200cm biliary limb

    Other: Ten year evaluation

Interventions

  • OtherTen year evaluation

    Clinical, biological and endoscopic evaluation

06

What researchers measure

Primary outcomes

  1. Incidence of serious surgery-related adverse events

    A serious adverse event is defined as a medical event that requires hospitalization, is life-threatening, results in persistent or substantial disability, or results in death. The "surgery-related" character will be described by each investigator in the first instance and homogenized by the group of experts designated at the beginning of the study.

    Time frame: 10 years after surgery

Secondary outcomes

  1. incidence of serious adverse events not related to surgery

    Time frame: 10 years after surgery

  2. Nutritional biological status , assessed by evaluation of malnutrition parameters

    Time frame: 10 years after surgery

  3. Nutritional clinical status, assessed by dietitian evaluation

    Time frame: 10 years after surgery

  4. Excess weight loss percentage

    calculated as follows: (weight at 10 years - initial weight) / (initial weight - ideal weight) x 100 The ideal weight is defined as the weight corresponding to a BMI = 25 kg/m2. The initial weight is the weight on the day of surgery.

    Time frame: 10 years after surgery

  5. Metabolic comorbidities remission

    Time frame: 10 years after surgery

  6. Diabetes remission

    Time frame: 10 years after surgery

  7. Hypertension remission

    Time frame: 10 years after surgery

  8. Obstructive sleep apnea remission

    Time frame: 10 years after surgery

  9. Dyslipidemia remission

    Time frame: 10 years after surgery

  10. Quality of life by BAROS score (Bariatric analysis and reporting outcome system)

    Time frame: 10 years after surgery

  11. Quality of life by GIQLI score (Gastro Intestinal Quality of Life index) questionnaires

    The GIQLI is a score to evaluate digestive disorders in 36 items, ranging from 0 (the worst quality of life) to 144 (the best quality of life).

    Time frame: 10 years after surgery

  12. GERD

    GERD, assessed by clinical evaluation, PPI use, and endoscopic signs of GERD (gastritis, oesophagitis, anastomotic ulcer, Barrett's esophagus, gastric metaplasia, esophageal metaplasia

    Time frame: 10 years after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Jul 2026, 58 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 58 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2021
First posted
Jun 18, 2021
StartActual
Sep 15, 2021
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04930029
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Sep 15, 2021
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Dec 26, 2025

Study contacts

Robert CAIAZZO, MD,PhD
Contact
robert.caiazzo@chru-lille.fr
0320445962 ext. +33
Robert CAIAZZO, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion